X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lenalidomide (3222) 3222
index medicus (2531) 2531
humans (2529) 2529
hematology (1788) 1788
oncology (1728) 1728
multiple myeloma (1695) 1695
bortezomib (1176) 1176
male (1136) 1136
female (1132) 1132
thalidomide - analogs & derivatives (1127) 1127
multiple myeloma - drug therapy (1071) 1071
aged (1036) 1036
thalidomide (1029) 1029
middle aged (982) 982
dexamethasone (802) 802
treatment outcome (722) 722
therapy (708) 708
antineoplastic combined chemotherapy protocols - therapeutic use (693) 693
adult (656) 656
stem-cell transplantation (649) 649
thalidomide - therapeutic use (624) 624
thalidomide - administration & dosage (560) 560
survival (553) 553
antineoplastic agents - therapeutic use (537) 537
lenalidomide plus dexamethasone (523) 523
cancer (522) 522
care and treatment (513) 513
aged, 80 and over (494) 494
chemotherapy (466) 466
transplantation (454) 454
multiple myeloma - therapy (395) 395
prognosis (383) 383
multiple-myeloma (376) 376
thalidomide - adverse effects (363) 363
multiple myeloma - pathology (341) 341
hematology, oncology and palliative medicine (333) 333
dexamethasone - administration & dosage (326) 326
combination (322) 322
medicine & public health (318) 318
multiple myeloma - mortality (315) 315
drug therapy (302) 302
pharmacology & pharmacy (302) 302
open-label (300) 300
recurrence (290) 290
analysis (282) 282
stem cells (281) 281
antineoplastic combined chemotherapy protocols - adverse effects (276) 276
disease-free survival (273) 273
myelodysplastic syndromes (273) 273
article (272) 272
pomalidomide (267) 267
research (267) 267
trial (263) 263
animals (262) 262
patients (254) 254
immunologic factors - therapeutic use (248) 248
elderly-patients (247) 247
plus dexamethasone (247) 247
multiple myeloma - diagnosis (240) 240
retrospective studies (236) 236
rituximab (233) 233
angiogenesis inhibitors (232) 232
abridged index medicus (228) 228
myeloma (226) 226
risk factors (225) 225
immunology (224) 224
leukemia (214) 214
antineoplastic agents - adverse effects (210) 210
melphalan (210) 210
carfilzomib (209) 209
low-dose dexamethasone (207) 207
clinical trials (204) 204
efficacy (202) 202
stem cell transplantation (201) 201
thalidomide - pharmacology (201) 201
cyclophosphamide (200) 200
hemic and lymphatic diseases (194) 194
phase-ii (194) 194
health aspects (192) 192
survival analysis (192) 192
transplantation, autologous (188) 188
clinical trials as topic (183) 183
maintenance (182) 182
prednisone (181) 181
survival rate (181) 181
combination therapy (176) 176
diagnosis (174) 174
hematopoietic stem cell transplantation (173) 173
antineoplastic agents - pharmacology (170) 170
immunotherapy (170) 170
risk (169) 169
myelodysplastic syndrome (168) 168
relapse (168) 168
medicine, general & internal (167) 167
autologous transplantation (166) 166
myelodysplastic syndromes - drug therapy (163) 163
lymphomas (160) 160
antineoplastic combined chemotherapy protocols - administration & dosage (159) 159
immunomodulatory drugs (158) 158
follow-up studies (157) 157
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3839) 3839
German (61) 61
French (41) 41
Polish (34) 34
Czech (19) 19
Japanese (19) 19
Russian (18) 18
Spanish (17) 17
Chinese (6) 6
Korean (4) 4
Hungarian (3) 3
Slovak (3) 3
Turkish (2) 2
Portuguese (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Neri, P
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 2, pp. 105 - 106
In this issue of Blood, Sperling et al describe the biological determinants underlying the activity of thalidomide analogs in a given cell and potential... 
LENALIDOMIDE | HEMATOLOGY | DEGRADATION
Journal Article
HAEMATOLOGICA, ISSN 0390-6078, 01/2017, Volume 102, Issue 1, pp. 160 - 167
POEMS syndrome is a rare para-neoplastic syndrome secondary to a plasma cell dyscrasia. Effective treatment can control the disease-related symptom complex. We... 
EFFICACY | LENALIDOMIDE | THALIDOMIDE | HEMATOLOGY
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1584 - 1586
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3776 - 3783
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM).... 
LENALIDOMIDE | FAMILY PROTEINS | BORTEZOMIB | ONCOLOGY
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2014, Volume 12, Issue 5.5, pp. 808 - 811
Studies on multiple myeloma reported in 2013 offer support for maintenance after induction and consolidation in newly diagnosed patients eligible for... 
ONCOLOGY | LENALIDOMIDE
Journal Article
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 2019, Volume 42, Issue 5, pp. 294 - 295
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 06/2018, Volume 41, Issue 6, pp. 412 - 412
Journal Article
NATURE, ISSN 0028-0836, 08/2014, Volume 512, Issue 7512, pp. 49 - 49
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the... 
MULTIPLE-MYELOMA | CELLS | PROTEIN | MENTAL-RETARDATION | RECOGNITION | MULTIDISCIPLINARY SCIENCES | LENALIDOMIDE | CEREBLON | POMALIDOMIDE | CANCER | CONGENITAL ABNORMALITIES
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2018, Volume 61, Issue 2, pp. 535 - 542
Journal Article
The Oncologist, ISSN 1083-7159, 01/2010, Volume 15, Issue 1, pp. 6 - 25
Journal Article
JNCI: Journal of the National Cancer Institute, ISSN 0027-8874, 01/2019, Volume 111, Issue 1, pp. 7 - 8
Journal Article
Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 2, pp. 228 - 245
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2014, Volume 164, Issue 6, pp. 811 - 821
Summary Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex,... 
lenalidomide | Cereblon | Ikaros | pomalidomide | Aiolos | Pomalidomide | Lenalidomide | Ubiquitin | Genetic transcription | T cells | Ligases | Analysis | Haematological Malignancy
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2015, Volume 13, Issue 5.5, pp. 666 - 669
As targeted therapy in B-cell lymphomas rapidly expands beyond anti-CD20 monoclonal antibodies, many newer types of agents are in various stages of... 
ONCOLOGY | INDOLENT LYMPHOMA | LENALIDOMIDE
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 09/2017, Volume 104, Issue 9, pp. 814 - 816
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 04/2017, Volume 40, Issue 4, pp. 226 - 227
Journal Article
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 02/2017, Volume 40, Issue 1-2, pp. 66 - 66
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.